New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines

Breast Cancer Research and Treatment

Volumn 124, Issue 1, 2010, Pages 101-110

  Colin, Christelle ^a   Salamone, Stéphane ^b   Grillier Vuissoz, Isabelle ^a   Boisbrun, Michel ^b   Kuntz, Sandra ^a   Lecomte, Julie ^a   Chapleur, Yves ^b   Flament, Stéphane ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b NANCY UNIVERSITÉ   (France)

Author keywords

Biotin; Breast cancer; Cyclin D1; PPAR ; Troglitazone

Indexed keywords

BIOTIN; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; TROGLITAZONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOTINYLATION; BREAST CANCER; CANCER CELL; CELL COUNT; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANTINEOPLASTIC AGENTS; BIOTINYLATION; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMANS; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; NEOPLASMS, HORMONE-DEPENDENT; PPAR GAMMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; THIAZOLIDINEDIONES; TRANSFECTION;

EID: 77957719908     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0700-y     Document Type: Article

References (42)

1. T Sørlie 2004 Molecular portraits of breast cancer: tumour subtypes as distinct disease entities Eur J Cancer 40 18 2667 2675 10.1016/j.ejca.2004.08.021 15571950
2. Early Breast Cancer Trialist' Collaborative Group (EBCTC) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0
3. R Nahta FJ Esteva 2006 Herceptin: mechanisms of action and resistance Cancer Lett 232 2 123 138 1:CAS:528:DC%2BD28XhtFWhurg%3D 10.1016/j.canlet.2005. 01.041 16458110
4. HJ Burstein GD Demetri E Mueller, et al. 2003 Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand TGZ as treatment for refractory breast cancer: a phase II study Breast Cancer Res Treat 79 391 397 1:CAS:528:DC%2BD3sXktlagsrs%3D 10.1023/A:1024038127156 12846423
5. LD Yee N Williams P Wen, et al. 2007 Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum marker Clin Cancer Res 13 246 252 1:CAS:528:DC%2BD2sXotlWh 10.1158/1078-0432.CCR-06-1947 17200362
6. DJ Mangelsdorf C Thummel M Beato, et al. 1995 The nuclear receptor superfamily: the second decade Cell 83 835 839 1:CAS:528:DyaK2MXhtVSnu7nJ 10.1016/0092-8674(95)90199-X 8521507
7. I Isseman S Green 1990 Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 347 645 650 10.1038/347645a0
8. SA Kliewer BM Forman B Blumberg, et al. 1994 Differential expression and activation of a family of murine peroxisome proliferators-activated receptors Proc Natl Acad Sci USA 91 7355 7359 1:CAS:528:DyaK2cXmsFajtb0%3D 10.1073/pnas.91.15.7355 8041794
9. C Dreyer G Krey H Keller, et al. 1992 Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors Cell 68 879 887 1:CAS:528:DyaK3sXitV2lsbg%3D 10.1016/0092-8674(92)90031-7 1312391
10. I Issemann RA Prince JD Tugwood, et al. 1993 The retinoid X receptor enhances the function of the peroxisome proliferator activated receptor Biochimie 75 251 256 1:CAS:528:DyaK3sXkt1Wit7Y%3D 10.1016/0300-9084(93)90084-6 8389594
11. DJ Mangelsdorf RM Evans 1995 The RXR heterodimers and orphan receptors Cell 83 841 850 1:CAS:528:DyaK2MXhtVSnu7nK 10.1016/0092-8674(95)90200-7 8521508
12. NJ McKenna BW O'Malley 2002 Minireview: nuclear receptor coactivators-an update Endocrinology 43 2461 2465 10.1210/en.143.7.2461
13. W Yang C Rachez LP Freedman 2000 Discrete roles for peroxisome proliferator-activated receptor gamma and retinoid X receptor in recruiting nuclear receptor coactivators Mol Cell Biol 20 8008 8017 1:CAS:528: DC%2BD3cXnslOjsb0%3D 10.1128/MCB.20.21.8008-8017.2000 11027271
14. SR Thoennes PL Tate TM Price, et al. 2000 Differential transcriptional activation of peroxisome proliferator-activated receptor gamma by omega-3 and omega-6 fatty acids in MCF-7 cells Mol Cell Endocrinol 160 67 73 1:CAS:528:DC%2BD3cXhslersbs%3D 10.1016/S0303-7207(99)00254-3 10715540
15. BM Forman P Tontonoz J Chen, et al. 1995 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma Cell 83 803 812 1:CAS:528:DyaK2MXpvVehtLc%3D 10.1016/0092-8674(95)90193-0 8521497
16. SA Kliewer JM Lenhard TM Willson, et al. 1995 A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation Cell 83 813 819 1:CAS:528:DyaK2MXpvVehtb4%3D 10.1016/0092-8674(95)90194-9 8521498
17. BM Spiegelman 1998 PPAR-gamma: adipogenic regulator and thiazolidinedione receptor Diabetes 47 507 514 1:CAS:528:DyaK1cXit1Gnsrk%3D 10.2337/diabetes.47. 4.507 9568680
18. KY Kim SS Kim HG Cheon 2006 Differential anti-proliferative actions of peroxisome proliferator-activated receptor-gamma agonists in MCF-7 breast cancer cells Biochem Pharmacol 72 530 540 1:CAS:528:DC%2BD28Xot1ahsrc%3D 10.1016/j.bcp.2006.05.009 16806087
19. E Elstner C Muller K Koshizuka, et al. 1998 Ligands for peroxisome proliferators-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice Proc Natl Acad Sci USA 95 8806 8811 1:CAS:528:DyaK1cXkvFaltr4%3D 10.1073/pnas.95.15.8806 9671760
20. E Mueller P Sarraf P Tontonoz, et al. 1998 Terminal differentiation of human breast cancer through PPARγ Mol Cell 1 465 470 1:CAS:528: DyaK1cXhtlyhurk%3D 10.1016/S1097-2765(00)80047-7 9660931
21. RG Mehta E Williamson MK Patel, et al. 2000 A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions J Natl Cancer Inst 92 418 423 1:CAS:528: DC%2BD3cXhvFGhu7o%3D 10.1093/jnci/92.5.418 10699072
22. MH Fenner E Elstner 2005 Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer Expert Opin Invest Drugs 14 557 568 1:CAS:528:DC%2BD2MXkvV2ntL4%3D 10.1517/13543784.14.6.557
23. F Yin S Wakino Z Liu, et al. 2001 TGZ inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators Biochem Biophys Res Commun 286 916 922 1:CAS:528:DC%2BD3MXmtlejtL4%3D 10.1006/bbrc.2001.5491 11527386
24. R Kar PK Singha MA Venkatachalam, et al. 2009 A novel role for MAP1 LC3 in nonautophagic cytoplasmic vacuolation death of cancer cells Oncogene 28 28 2556 2568 1:CAS:528:DC%2BD1MXmtVOrtbY%3D 10.1038/onc.2009.118 19448671
25. J Zhou W Zhang B Liang, et al. 2009 PPARgamma activation induces autophagy in breast cancer cells Int J Biochem Cell Biol 41 11 2334 2342 1:CAS:528:DC%2BD1MXhtFyntLvJ 10.1016/j.biocel.2009.06.007 19563910
26. S Goetze XP Xi H Kawano, et al. 1999 PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells J Cardiovasc Pharmacol 33 798 806 1:CAS:528:DyaK1MXislGgsbY%3D 10.1097/00005344-199905000-00018 10226869
27. X Xin S Yang J Kowalski, et al. 1999 Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo J Biol Chem 274 9116 9121 1:CAS:528:DyaK1MXitFyru7c%3D 10.1074/jbc.274.13. 9116 10085162
28. C Blanquicett J Roman CM Hart 2008 Thiazolidinediones as anti-cancer agents Cancer Ther 6 A 25 34 1:CAS:528:DC%2BD1cXht1KgsbfL 19079765
29. S Wei J Yang SL Lee, et al. 2009 PPARgamma-independent antitumor effects of thiazolidinediones Cancer Lett 276 2 119 124 1:CAS:528:DC%2BD1MXisFKjsL8%3D 10.1016/j.canlet.2008.08.008 18790559
30. CE Clay A Monjazeb J Thorburn, et al. 2002 15-Deoxy-delta12, 14-prostaglandin J2-induced apoptosis does not require PPARgamma in breast cancer cells J Lipid Res 43 11 1818 1828 1:CAS:528:DC%2BD38Xos1yhtrk%3D 10.1194/jlr.M200224-JLR200 12401880
31. CW Shiau CC Yang SK Kulp, et al. 2005 Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma Cancer Res 65 4 1561 1569 1:CAS:528:DC%2BD2MXhsFKqtbo%3D 10.1158/0008-5472.CAN-04-1677 15735046
32. J Lecomte S Flament S Salamone, et al. 2008 Disruption of ERα signalling pathway by PPARγ agonists: evidences of PPARγ-independent events in two hormone-dependent breast cancer cell lines Breast Cancer Res Treat 112 437 451 1:CAS:528:DC%2BD1cXhtl2mu7nF 10.1007/s10549-007-9886-z 18204896
33. CC Yang CY Ku S Wei, et al. 2006 Peroxisome proliferator-activated receptor gamma-independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells Mol Pharmacol 69 5 1564 1570 1:CAS:528:DC%2BD28XksVWrt70%3D 10.1124/mol.105.018333 16452400
34. JW Huang CW Shiau YT Yang, et al. 2005 Peroxisome proliferator-activated receptor γ-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells Mol Pharmacol 67 1342 1348 1:CAS:528:DC%2BD2MXjtFWmsbo%3D 10.1124/mol.104.007732 15653552
35. G Russell-Jones K McTavish J McEwan, et al. 2004 Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours J Inorg Biochem 98 10 1625 1633 1:CAS:528:DC%2BD2cXotF2mtbg%3D 10.1016/j.jinorgbio.2004. 07.009 15458825
36. W Yang Y Cheng T Xu, et al. 2009 Targeting cancer cells with biotin-dendrimer conjugates Eur J Med Chem 44 2 862 868 1:CAS:528: DC%2BD1MXitlWjtbs%3D 10.1016/j.ejmech.2008.04.021 18550227
37. D Boschi GC Tron L Lazzarato, et al. 2006 NO-donor phenols: a new class of products endowed with antioxidant and vasodilator properties J Med Chem 49 2886 2897 1:CAS:528:DC%2BD28XjslKltLk%3D 10.1021/jm0510530 16686532
38. JW Huang CW Shiau J Yang, et al. 2006 Development of small-molecule cyclin D1-ablative agents J Med Chem 49 4684 4689 1:CAS:528:DC%2BD28XmsVeltbc%3D 10.1021/jm060057h 16854074
39. F Turturro E Friday R Fowler, et al. 2004 Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferator-activated receptor gamma-independent mechanism in breast cancer-derived cell lines Clin Cancer Res 10 20 7022 7030 1:CAS:528:DC%2BD2cXpslGlurk%3D 10.1158/1078-0432.CCR-04-0879 15501982
40. J Yang S Wei DS Wang, et al. 2008 Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents J Med Chem 51 7 2100 2107 1:CAS:528:DC%2BD1cXjt1Wqs7s%3D 10.1021/jm701212m 18335975
41. HJ Kim JY Kim Z Meng, et al. 2007 15-deoxy-Delta 12, 14-prostaglandin J2 inhibits transcriptional activity of estrogen receptor-alpha via covalent modification of DNA-binding domain Cancer Res 67 2595 2602 1:CAS:528: DC%2BD2sXivV2nsrg%3D 10.1158/0008-5472.CAN-06-3043 17363578
42. V Kansara S Luo B Balasubrahmanyam, et al. 2006 Biotin uptake and cellular translocation in human derived retinoblastoma cell line (Y-79): a role of hSMVT system Int J Pharm 312 1-2 43 52 1:CAS:528:DC%2BD28XisFeqtL8%3D 10.1016/j.ijpharm.2005.12.045 16459033